News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
265,251 Results
Type
Article (13763)
Company Profile (101)
Press Release (251387)
Section
Business (88041)
Career Advice (465)
Deals (15342)
Drug Delivery (67)
Drug Development (36601)
Employer Resources (49)
FDA (6289)
Job Trends (6197)
News (150207)
Policy (14027)
Tag
2024 BioCapital Digital (8)
2024 BioForest Digital (3)
2024 BioForest Standard (1)
2024 BioMidwest Digital (3)
2024 BioMidwest Standard (1)
2024 Bio NC Digital (3)
2024 Bio NC Standard (1)
2024 Biotech Bay Standard (7)
2024 Biotech Beach Digital (4)
2024 Biotech Beach Standard (1)
2024 Genetown Digital (3)
2024 Genetown Standard (3)
2024 Lone Star Bio Digital (2)
2024 Pharm Country Digital (2)
2024 Pharm Country Standard (2)
2025 BioForest Digital (2)
2025 Lone Star Bio Digital (4)
2026 BioCapital Standard (1)
2026 Biotech Bay Standard (1)
2026 Pharm Country Standard (1)
Academia (440)
Accelerated approval (2)
Adcomms (6)
Allergies (32)
Alliances (23214)
ALS (36)
Alzheimer's disease (390)
Antibody-drug conjugate (ADC) (37)
Approvals (6326)
Artificial intelligence (104)
Autoimmune disease (8)
Automation (3)
Bankruptcy (149)
Best Places to Work (4370)
BIOSECURE Act (9)
Biosimilars (55)
Biotechnology (40)
Bladder cancer (19)
Brain cancer (15)
Breast cancer (74)
Cancer (585)
Cardiovascular disease (70)
Career advice (407)
Career pathing (11)
CAR-T (21)
Cell therapy (85)
Cervical cancer (4)
Clinical research (30881)
Collaboration (325)
Compensation (138)
Complete response letters (17)
COVID-19 (757)
CRISPR (19)
C-suite (117)
Cystic fibrosis (35)
Data (607)
Denatured (15)
Depression (9)
Diabetes (77)
Diagnostics (1317)
Diversity (2)
Diversity, equity & inclusion (13)
Drug discovery (55)
Drug pricing (63)
Drug shortages (12)
Duchenne muscular dystrophy (33)
Earnings (32082)
Editorial (11)
Employer branding (4)
Employer resources (43)
Events (37416)
Executive appointments (359)
FDA (6687)
Featured Employer (20)
Friedreich's ataxia (2)
Frontotemporal dementia (1)
Funding (205)
Gene editing (37)
Generative AI (8)
Gene therapy (100)
GLP-1 (339)
Government (1286)
Grass and pollen (2)
Guidances (15)
Healthcare (3564)
Huntington's disease (4)
IgA nephropathy (11)
Immunology and inflammation (34)
Indications (12)
Infectious disease (790)
Inflammatory bowel disease (54)
Inflation Reduction Act (6)
Influenza (13)
Intellectual property (45)
Interviews (59)
IPO (5874)
IRA (29)
Job creations (2050)
Job search strategy (373)
Kidney cancer (6)
Labor market (10)
Layoffs (178)
Leadership (3)
Legal (3429)
Liver cancer (19)
Lung cancer (79)
Lymphoma (52)
Machine learning (1)
Management (16)
Manufacturing (143)
MASH (31)
Medical device (1275)
Medtech (1277)
Mergers & acquisitions (9658)
Metabolic disorders (246)
Multiple sclerosis (20)
NASH (14)
Neurodegenerative disease (22)
Neuropsychiatric disorders (6)
Neuroscience (563)
NextGen: Class of 2025 (1586)
Non-profit (593)
Northern California (680)
Now hiring (7)
Obesity (140)
Opinion (118)
Ovarian cancer (21)
Pain (50)
Pancreatic cancer (13)
Parkinson's disease (44)
Partnered (7)
Patents (104)
Patient recruitment (28)
Peanut (10)
People (28876)
Pharmaceutical (64)
Pharmacy benefit managers (11)
Phase I (8037)
Phase II (13062)
Phase III (11729)
Pipeline (416)
Podcasts (46)
Policy (59)
Postmarket research (1401)
Preclinical (3211)
Press Release (25)
Prostate cancer (44)
Psychedelics (8)
Radiopharmaceuticals (120)
Rare diseases (158)
Real estate (2634)
Recruiting (17)
Regulatory (10090)
Reports (14)
Research institute (564)
Resumes & cover letters (55)
Rett syndrome (1)
RNA editing (2)
RSV (7)
Schizophrenia (35)
Series A (36)
Series B (11)
Service/supplier (3)
Sickle cell disease (31)
Southern California (695)
Special edition (6)
Spinal muscular atrophy (77)
Sponsored (6)
Startups (1627)
State (2)
Stomach cancer (3)
Supply chain (28)
Tariffs (10)
The Weekly (29)
United States (6902)
Vaccines (150)
Venture capitalists (13)
Webinars (10)
Weight loss (95)
Women's health (8)
Worklife (3)
Date
Today (23)
Last 7 days (245)
Last 30 days (927)
Last 365 days (11998)
2025 (3095)
2024 (12502)
2023 (14247)
2022 (19556)
2021 (20068)
2020 (19032)
2019 (14885)
2018 (11713)
2017 (13888)
2016 (13129)
2015 (15474)
2014 (12423)
2013 (10593)
2012 (11401)
2011 (11923)
2010 (10888)
Location
Africa (313)
Alabama (13)
Alaska (1)
Arizona (54)
Arkansas (3)
Asia (20093)
Australia (2606)
California (1643)
Canada (874)
China (231)
Colorado (65)
Connecticut (65)
Delaware (53)
Europe (39369)
Florida (308)
Georgia (36)
Idaho (9)
Illinois (186)
India (15)
Indiana (129)
Iowa (1)
Japan (86)
Kansas (56)
Kentucky (12)
Louisiana (1)
Maine (2)
Maryland (245)
Massachusetts (1424)
Michigan (28)
Minnesota (90)
Missouri (23)
Montana (8)
Nebraska (6)
Nevada (7)
New Hampshire (6)
New Jersey (726)
New Mexico (7)
New York (482)
North Carolina (381)
North Dakota (2)
Northern California (680)
Ohio (48)
Oklahoma (4)
Oregon (16)
Pennsylvania (416)
Puerto Rico (8)
Rhode Island (7)
South America (501)
South Carolina (2)
Southern California (695)
Tennessee (34)
Texas (219)
Utah (33)
Virginia (70)
Washington D.C. (29)
Washington State (112)
Wisconsin (14)
265,251 Results for "dizal pharmaceutical".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Dizal Announces DZD8586 and DZD6008 Presentations at 2025 ASCO Annual Meeting
April 1, 2025
·
4 min read
Press Releases
Dizal’s Golidocitinib in Combination with Anti-PD-1 Shows Promise in IO Resistant Non-Small Cell Lung Cancer
March 20, 2025
·
7 min read
Press Releases
U.S. FDA Granted Priority Review to Dizal’s Sunvozertinib New Drug Application
January 7, 2025
·
5 min read
Press Releases
Dizal Announces Positive Pooled Data of Sunvozertinib in EGFR Tyrosine Kinase Inhibitor-Resistant Non-Small Cell Lung Cancer Published in Lung Cancer
December 11, 2024
·
5 min read
Press Releases
Dizal Presents Latest Data of DZD8586, a LYN/BTK Dual Inhibitor, in B-cell Non-Hodgkin Lymphoma at the 2024 ASH Annual Meeting
December 9, 2024
·
6 min read
Dizal Reveals New Findings from Biomarker Analysis, Highlighting Sunvozertinib as an Effective Treatment for Non-small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
Dizal announced new findings from a biomarker study in non-small cell lung cancer patients with exon 20 insertion mutations, highlighting sunvozertinib as an effective treatment for this patient population.
May 24, 2024
·
6 min read
Press Releases
Dizal Submits New Drug Application to the U.S. FDA for Sunvozertinib in Treating Relapsed or Refractory Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
November 8, 2024
·
5 min read
Dizal’s Sunvozertinib Pivotal Study Results Published in The Lancet Respiratory Medicine
Dizal announced that the results of a phase 2 pivotal study of sunvozertinib for the treatment of platinum-pretreated non-small-cell lung cancer patients with EGFR exon 20 insertion mutations were published in the peer-reviewed journal The Lancet Respiratory Medicine.
December 13, 2023
·
6 min read
Breakthrough in Lung Cancer Treatment: Dizal to Unveil Groundbreaking Results of Sunvozertinib for Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations at 2024 ASCO Annual Meeting
Dizal (SSE:688192) announced today that two abstracts featuring the latest data on sunvozertinib in non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion (exon20ins) mutations will be presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting on May 31 through June 4 in Chicago.
April 24, 2024
·
6 min read
Business
Anova Partners with Dizal (Jiangsu) Pharmaceuticals to Accelerate Development of DZD9008 for Patients with Advanced or Metastatic NSCLC with EGFR Exon20 insertion Mutation
Anova Enterprises, Inc. (Anova), an organization dedicated to accelerating promising treatments to market with its transformative AnovaOS™ technology platform, and the industry’s first collaborative ‘learning system’, today announced a partnership with Dizal Pharmaceuticals (Dizal) to accelerate the development of DZD9008 for patients with EGFR Exon20ins mutant NSCLC.
September 6, 2023
·
4 min read
1 of 26,526
Next
